Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
Volume 49, Issue -, Pages 327-347Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.pharmtox.011008.145634
Keywords
monoamine; serotonin; dopamine; signaling; psychiatric disorders
Categories
Funding
- National Institutes of Health [DA-13511, NS-19576, MH-73853, MH-40159, MH-82441]
- Canada Research Chair in Molecular Psychiatry
- Human Frontier Science Program Career Development
Ask authors/readers for more resources
Psychotropic drugs acting on monoamine neurotransmission are major pharmacological treatments for neuropsychiatric conditions such as schizophrenia, depression, bipolar disorder, Tourette syndrome, ADHD, and Alzheimer disease. Independent lines of research involving biochemical and behavioral approaches in normal and/or genetically modified mice provide converging evidence for an involvement of the signaling molecules Akt and glycogen synthase kinase-3 (GSK3) in the regulation of behavior by dopamine and serotonin (5-HT). These signaling molecules have also received attention for their role in the actions of psychoactive drugs such as antidepressants, antipsychotics, lithium, and other mood stabilizers. Furthermore, investigations of the mechanism by which D2 dopamine receptors regulate Akt/GSK3 signaling strongly support the physiological relevance of a new modality of G protein-coupled receptor (GPCR) signaling involving the multifunctional scaffolding protein beta-arrestin 2. Elucidation of the contribution of multiple signaling pathways to the action of psychotropic drugs may provide a better biological understanding of psychiatric disorders and lead to more efficient therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available